What does Bellipharma do?

Bellipharma is a pharmacy in Schaarbeek. Private Limited, started on 29 February 2012, 1 establishment.

What is the address of Bellipharma?

The registered office of Bellipharma is located at Simon Bolivarlaan 21-23, 1030 Schaarbeek.

Is Bellipharma still active?

Yes. According to the CBE (2 November 2026) Bellipharma is active, legal situation “Normale toestand”, started on 29 February 2012.

Is Bellipharma registered on Peppol?

Yes, Bellipharma is registered on the Peppol network with ID 0208:0844039461.

What is the enterprise number of Bellipharma?

The enterprise number of Bellipharma is BE0844039461.

When was Bellipharma founded?

Bellipharma was founded on 29 February 2012.

Who are the directors of Bellipharma?

According to the 2024 annual accounts, the directors of Bellipharma are: NOVESTA BV.

Is Bellipharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 29 February 2012; 4 annual accounts filed, latest fiscal year 2024; 1 directors known from the annual account.

How much profit did Bellipharma make in 2024?

Bellipharma recorded a loss after taxes of € 19,063 in financial year 2024.

What is the revenue of Bellipharma?

As a small company, Bellipharma is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 28,379.

Does Bellipharma have a website?

Yes, Bellipharma has a website at bellipharma.be.

Bellipharma (Private Limited) - Schaarbeek - BE0844039461

Dossier Bellipharma, printed on 2 November 2026 from databakkes.be/en/0844039461/bellipharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2023 and 2024.
Tight liquidity NBB

Cash and receivables cover 43 % of short-term debt in 2024; threshold 65 %.

Financials

Financial year 2024

Bellipharma from Schaarbeek, company number BE0844039461, closed financial year 2024 with a result of € -19,063 after tax. For that financial year Bellipharma recorded a gross margin of € 28,379 and equity of € 223,865. Compared with financial year 2023, the result moved from € -18,720 to € -19,063. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 17, 2025.

What it is worth Healthy

€ 223,865

▼ 8% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -19,063

▼ 2 % more loss than in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 44,182

▲ 36% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 43,265.

People and assets in 2024

Wage cost

€ 23,651

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2024

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 17,308

▼ 40% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 2,727

▼ 79% vs 2023

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Revenue	-	€ 637,289 Revenue 2022: € 637,289 First fiscal year in the series	-	-
Gross margin	€ 144,795 Gross margin 2021: € 144,795 First fiscal year in the series	€ 80,364 Gross margin 2022: € 80,364 ▼ 44% vs 2021 (€ 144,795) Unfavourable step	€ 5,821 Gross margin 2023: € 5,821 ▼ 93% vs 2022 (€ 80,364) Unfavourable step	€ 28,379 Gross margin 2024: € 28,379 ▲ € 22,558 vs 2023 (€ 5,821) Favourable step	▲ € 22,558
Profit after taxes	€ 99,286 Profit after taxes 2021: € 99,286 First fiscal year in the series	€ 24,650 Profit after taxes 2022: € 24,650 ▼ 75% vs 2021 (€ 99,286) Unfavourable step	€ -18,720 Profit after taxes 2023: € -18,720 ▼ € 43,370 vs 2022 (€ 24,650) Unfavourable step	€ -19,063 Profit after taxes 2024: € -19,063 ▼ € 343 vs 2023 (€ -18,720) Unfavourable step	▼ € 343
Equity	€ 236,997 Equity 2021: € 236,997 First fiscal year in the series	€ 261,648 Equity 2022: € 261,648 ▲ 10% vs 2021 (€ 236,997) Favourable step	€ 242,928 Equity 2023: € 242,928 ▼ 7% vs 2022 (€ 261,648) Unfavourable step	€ 223,865 Equity 2024: € 223,865 ▼ 8% vs 2023 (€ 242,928) Unfavourable step	▼ 8%
Total debts	€ 233,608 Total debts 2021: € 233,608 First fiscal year in the series	€ 237,378 Total debts 2022: € 237,378 ▲ 2% vs 2021 (€ 233,608) Unfavourable step	€ 158,365 Total debts 2023: € 158,365 ▼ 33% vs 2022 (€ 237,378) Favourable step	€ 224,421 Total debts 2024: € 224,421 ▲ 42% vs 2023 (€ 158,365) Unfavourable step	▲ 42%
Cash	€ 10,618 Cash 2021: € 10,618 First fiscal year in the series	€ 5,902 Cash 2022: € 5,902 ▼ 44% vs 2021 (€ 10,618) Unfavourable step	€ 32,569 Cash 2023: € 32,569 ▲ € 26,667 vs 2022 (€ 5,902) Favourable step	€ 44,182 Cash 2024: € 44,182 ▲ 36% vs 2023 (€ 32,569) Favourable step	▲ 36%
Retained profit	€ 56,397 Retained profit 2021: € 56,397 First fiscal year in the series	€ 81,048 Retained profit 2022: € 81,048 ▲ 44% vs 2021 (€ 56,397) Favourable step	€ 62,328 Retained profit 2023: € 62,328 ▼ 23% vs 2022 (€ 81,048) Unfavourable step	€ 43,265 Retained profit 2024: € 43,265 ▼ 31% vs 2023 (€ 62,328) Unfavourable step	▼ 31%
Bank debt	€ 205,241 Bank debt 2021: € 205,241 First fiscal year in the series	€ 155,208 Bank debt 2022: € 155,208 ▼ 24% vs 2021 (€ 205,241) Favourable step	€ 114,344 Bank debt 2023: € 114,344 ▼ 26% vs 2022 (€ 155,208) Favourable step	€ 0 Bank debt 2024: € 0 ▼ 100% vs 2023 (€ 114,344) Favourable step	▼ 100%
Balance sheet total	€ 470,606 Balance sheet total 2021: € 470,606 First fiscal year in the series	€ 499,026 Balance sheet total 2022: € 499,026 ▲ 6% vs 2021 (€ 470,606) Unchanged	€ 401,293 Balance sheet total 2023: € 401,293 ▼ 20% vs 2022 (€ 499,026) Unchanged	€ 448,286 Balance sheet total 2024: € 448,286 ▲ 12% vs 2023 (€ 401,293) Unchanged	▲ 12%

Key figures of Bellipharma, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to Bellipharma?

What happened at Bellipharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Dec 17, 2025 New annual accounts for financial year 2024: loss of € 19,063. filed late Source: NBB ↗
Feb 29, 2012 Start of the company according to the CBE. KBO
Feb 16, 2012 New establishment in Schaarbeek. KBO

In short

From € 99,286 profit in 2021 to € 19,063 loss in 2024.

Paid € 24,843 in corporate taxes since 2021.

Best year ever: 2021, with € 99,286 profit.

Original PDFs at the National Bank ↗

Management

Crown Consultancy 100%

The stake of Crown Consultancy comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Bellipharma

Behind Bellipharma is NOVESTA BV. The shares are held by Crown Consultancy (100%).

Directors

According to the 2024 annual accounts

NOVESTA BV

Director · represented by OMAR HIM

Also active at: BELLIPHARMA YSER

Shareholders

Crown Consultancy

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Simon Bolivarlaan 21-23

1030 Schaarbeek

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS bellipharma.be

Technologies

ApacheBootstrap

Hosting & Email

Email provider

OVH Mail

Hosting

INFOMANIAK-AS, CH

Website info

HTTPS Ja

Languages FR

Features

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ IPv6

Details

Company number: 0844.039.461
VAT number: BE 0844.039.461
Registered office: Simon Bolivarlaan 21-23, 1030 Schaarbeek
Names & denominations: Bellipharma
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 29 February 2012
Peppol: Active · Active since 30 Jan 2025
Contact: bellipharma.be [email protected] +32 2 203 22 88
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗